On August 7, Natera rose 8.15% in after-hours trading, trading at $298.0 USD/share, with turnover of $22.46 million. The move came after the company released its latest quarterly earnings on August 6 after the close.

Heading into the report, the Street consensus expected quarterly revenue of $661 million, representing 38.72% year-over-year growth, and an adjusted loss per share of $0.49. For context, the prior quarter delivered revenue of $697 million (up 38.82% YoY) with a gross margin of 64.71% and adjusted EPS of -$0.60. In May, the company raised its full-year revenue guidance to $2.74B-$2.82B, above the then-consensus estimate of $2.67B.

The positive after-hours reaction is further underpinned by a series of recent milestones for the company's core Signatera platform, including EU IVDR Class C certification, Japan PMDA clearance for colorectal cancer use, NCCN Category 1 recommendation in bladder cancer, and FDA companion diagnostic approval. Additionally, the company expanded clinical partnerships with Aveta Biomics and Eledon Pharmaceuticals to deploy Signatera and Prospera in phase 3 trials, reinforcing its leadership in the MRD testing space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)